Tacrolimus trough levels in kidney transplant recipients

BMC Nephrology

Table 2 Tacrolimus trough level according to demographic and clinical characteristics (N = 248)

Characteristics	Classification	Tacrolimus trough level
Characteristics	Classification	Mean	t or F	p	SD	t or F	p	CV	t or F	p
Sex	Male	6.03 ± 1.15	0.47	.638	1.44 ± 0.88		.635^†	0.23 ± 0.11		.633^†
Sex	Female	5.97 ± 0.93	0.47	.638	1.62 ± 1.35		.635^†	0.26 ± 0.18		.633^†
Type of donor	Deceased	6.05 ± 1.00	0.63	.530	1.48 ± 1.15		.541^†	0.24 ± 0.16		.167^†
Type of donor	Living	5.97 ± 1.13	0.63	.530	1.65 ± 1.13		.541^†	0.27 ± 0.15		.167^†
Retransplant	Yes	6.20 ± 1.36	0.70	.490	1.39 ± 1.20		.172^†	0.21 ± 0.13		.085^†
Retransplant	No	5.99 ± 1.04	0.70	.490	1.59 ± 0.13		.172^†	0.26 ± 0.16		.085^†
Pretransplant kidney disease	IgA nephropathy	5.87 ± 0.90	1.24	.289	1.46 ± 0.89		.369^‡	0.25 ± 0.14	0.70	.689^‡
	DM ESRD	6.34 ± 1.24			1.72 ± 0.91			0.27 ± 0.13
	Glomerular nephropathy	5.69 ± 1.16			1.38 ± 1.05			0.23 ± 0.12
	ADPKD	6.12 ± 0.89			1.46 ± 0.93			0.23 ± 0.12
	Unknown	5.97 ± 1.01			1.57 ± 1.38			0.25 ± 0.17
	HT	5.93 ± 1.25			1.19 ± 0.42			0.20 ± 0.05
	Others	6.16 ± 1.00			1.54 ± 1.18			0.25 ± 0.16
BMI	< 18.5	5.70 ± 1.19		.073^‡	1.39 ± 0.93		.390^‡	0.23 ± 0.12		.153^‡
	18.5–24.9	6.09 ± 1.03			1.48 ± 1.00			0.24 ± 0.13
	> 24.5	5.92 ± 1.11			1.64 ± 1.37			0.27 ± 0.17
Tacrolimus dose change	Yes	6.00 ± 1.06		.797^†	1.76 ± 1.33		<.001^†	0.28 ± 0.17		<.001^†
Tacrolimus dose change	No	6.01 ± 1.07		.797^†	1.36 ± 0.90		<.001^†	0.22 ± 0.12		<.001^†
Rejection	Yes	5.64 ± 0.90		.129^†	1.35 ± 0.61		.971^†	0.23 ± 0.07		.557^†
Rejection	No	6.02 ± 1.07		.129^†	1.52 ± 1.11		.971^†	0.24 ± 0.15		.557^†

^†Mann–Whitney U test; ^‡Kruskal–Wallis test
Abbreviations: ADPKD Autosomal dominant polycystic kidney disease; BMI Body mass index, CV Coefficient of variation, DM ESRD Diabetes mellitus end-stage renal disease, HT Hypertension, IgA Immunoglobulin A, SD Standard deviation

ISSN: 1471-2369